Sun Pharma signs licensing pact with Cassiopea
The Hindu
Sun Pharmaceutical Industries Ltd. and Cassiopea SpA, a specialty pharmaceutical company on Monday announced the signing of licence and supply agreements for Winlevi (clascoterone cream 1%) in the Uni
Sun Pharmaceutical Industries Ltd. and Cassiopea SpA, a specialty pharmaceutical company on Monday announced the signing of licence and supply agreements for Winlevi (clascoterone cream 1%) in the United States and Canada. Winlevi has been approved by the United States Food & Drug Administration (FDA) as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older. Under the terms of the agreements, Sun Pharma will have the exclusive right to commercialise Winlevi in the United States and Canada, and Cassiopea will be the exclusive supplier of the product.More Related News